Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Integrative molecular characterisation of S/R RCC to reveal determinants of poor prognosis and response to ICIs

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 18.02.20
Views: 300
Rating:

Dr Ziad Bakouny - Dana-Farber Cancer Institute, Boston, USA

Dr Ziad Bakouny speaks to ecancer at the 2020 ASCO GU meeting at San Francisco about a study looking at the integrative molecular characterisation of sarcomatoid and rhabdoid renal cell carcinoma (S/R RCC) to reveal determinants of poor prognosis and response to immune checkpoint inhibitors (ICI).

He explains that patients with sarcomatoid and rhabdoid are still doing poorly and not responding so well to targeted therapies, however it has been suggested by studies that there could be a benefit to this population in the use of immune checkpoint inhibitors.

Dr Bakouny reports that across all the data immune checkpoint inhibitors seemed to conferring a strong benefit to patients with sarcomatoid and rhabdoid renal cell carcinoma.

Related videos

follow us

SIOG metastatic renal cell carcinoma


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation